Published in

EMH Swiss Medical Publishers, Swiss Medical Weekly, 2011

DOI: 10.4414/smw.2011.13213

Links

Tools

Export citation

Search in Google Scholar

Low-dose recombinant factor VIIa for massive bleeding: A single centre observational cohort study with 73 patients

Journal article published in 2011 by Pirmin Schmid, Andrea Mordasini, Martin Luginbühl, Bruno Regli, Hans-Peter Kohler, Heinz Zimmermann, Daniel Inderbitzin, Andreas Hirt, Bernhard Lämmle ORCID, Lorenzo Alberio
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown. The aim of the study was to evaluate our in-house guideline recommending a low dose of 60 μg/kg for off-label use of rFVIIa.